New COVID PJ.2.1 Variant Spreading Globally: Should You Be Worried About A Winter Surge?
A new COVID-19 variant, PJ.2.1, is drawing attention as it spreads across several countries, raising concerns about another seasonal rise in infections. First identified in Ontario, Canada, in May 2026, the variant has s
بقلم Tanya Dutt··25K قراءة
New COVID PJ.2.1 Variant Spreading Globally: Should You Be Worried About A Winter Surge?
A new COVID-19 variant, PJ.2.1, is drawing attention as it spreads across several countries, raising concerns about another seasonal rise in infections. First identified in Ontario, Canada, in May 2026, the variant has since been detected in parts of North America, Europe and Asia.
Early laboratory findings suggest that it may bind more efficiently to human cells, but researchers have not found evidence that it causes more severe illness or substantially escapes vaccine-induced immunity.
The development comes as health authorities prepare for the winter respiratory virus season, when people tend to spend more time indoors and infections such as COVID-19, influenza and respiratory syncytial virus (RSV) can circulate more easily. The UK Health Security Agency (UKHSA) has also reported a rise in COVID-19 activity, with positive test rates reaching around 7% in September and hospital admissions increasing by approximately 50% over the same period. However, the agency says current evidence does not suggest that the variants in circulation are causing more severe illness than previous ones.
A shopper wearing a protective face mask walks on Oxford Street in London, Britain. (REUTERS/File)
What Is The New COVID-19 Variant PJ.2.1?
PJ.2.1 is a lineage of SARS-CoV-2, the virus responsible for COVID-19. According to research published in the Journal of Infection in October 2026, it is a descendant of the JN.1 lineage and was first documented in a sample collected in Ontario, Canada, on May 2, 2026.
Since then, detections have been reported in the United States, Spain, France, Israel, Singapore, Australia and New Zealand, among other locations. Public Health Ontario’s genomic surveillance data showed that PJ.2.1 accounted for 25.2% of sequenced COVID-19 samples between September 20 and October 17, compared with 16.9% in the preceding four weeks.
The variant is attracting scientific attention because of changes in its spike protein, which the virus uses to attach to human cells. Laboratory research suggests PJ.2.1 may bind more efficiently to the ACE2 receptor, potentially giving it a growth advantage. However, laboratory findings alone cannot establish how easily it spreads between people or how severe an infection may become.
PJ.2.1 COVID-19 Symptoms
There is currently insufficient clinical evidence to establish that PJ.2.1 causes more severe illness, increases hospitalisations or leads to more deaths than other circulating variants.
Researchers have also not identified a distinct set of symptoms associated with this lineage. People infected with PJ.2.1 may experience symptoms commonly reported with COVID-19, including:
Fever or chills
Sore throat
Cough
Runny or blocked nose
Headache
Muscle and body aches
Fatigue and weakness
Swine Flu Cases Surge In Delhi-NCR
Some people may also experience shortness of breath, gastrointestinal symptoms or changes in their sense of taste or smell.
The World Health Organization (WHO) points out that COVID-19 symptoms can overlap with those of influenza and other respiratory infections. This means symptoms alone cannot reliably identify which virus is responsible. Testing may be needed to confirm an infection.
Are Existing COVID-19 Vaccines Still Effective Against New Variants?
Early laboratory findings offer some reassurance about PJ.2.1. Researchers found that antibodies from people who had received an LP.8.1-adapted COVID-19 vaccine could still neutralise the variant. Its sensitivity to neutralisation was 1.8 times lower than that of the LP.8.1 reference variant, suggesting some reduction in antibody activity but not a dramatic loss of recognition.
However, laboratory results do not establish how effectively a vaccine prevents infection in real-world conditions. Vaccination remains important because it helps reduce the risk of severe disease and hospitalisation. The WHO recommends a risk-based approach, with particular attention to older adults and people with underlying health conditions or weakened immunity.
Could A New COVID Wave Hit During Winter?
A rise in infections during winter is possible, but it is not necessarily evidence that a new variant is causing a more dangerous outbreak. Colder weather, increased time spent indoors and waning immunity from previous infections or vaccinations can contribute to the circulation of respiratory viruses.
The UKHSA has noted that COVID-19 activity has increased alongside hospital admissions this season. However, admissions have risen in line with overall infection levels rather than showing a disproportionate increase that would suggest a more severe variant.
In its assessment of the winter season, the agency also highlighted other variants, including XFG, commonly referred to as Stratus, and BA.3.2, sometimes called Cicada. XFG remains the most common variant in the UK, while the WHO has designated BA.3.2 as a Variant Under Monitoring. The WHO has assessed the public health risk from BA.3.2 as low, although evidence remains limited. These lineages should not be confused with PJ.2.1, which is a separate emerging variant.